Clinical Trial: NCT03150875
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Innovent Biologics (Suzhou) Co. Ltd. |
| Information Provided By: | Innovent Biologics (Suzhou) Co. Ltd. |
| Last Update Posted: | 2023-02-28 |
Study Overview
Brief Summary
Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
Additionally, the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC patients as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed
Official Title
Conditions
Intervention / Treatment
- Drug: IBI308
- Drug: Docetaxel
Other Study ID Numbers
- CIBI308C301
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Innovent Biologics (Suzhou) Co. Ltd. |
| Information Provided By: | Innovent Biologics (Suzhou) Co. Ltd. |
| Last Update Posted: | 2023-02-28 |
Study Overview
Brief Summary
Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
Additionally, the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC patients as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed
Official Title
Conditions
Intervention / Treatment
- Drug: IBI308
- Drug: Docetaxel
Other Study ID Numbers
- CIBI308C301